Home LiteratureArticle Details
PMID: 18040838 Published · ppublish English Editorial Research Support, Non-U.S. Gov't Review

Recent developments in cell-based immune therapy for neuroblastoma.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology ·Vol. 2 ·No. 2 ·2007-06-00 ·Pages 134-9

Verneris MR, Wagner JE

Abstract

Neuroblastoma (NB) is a common and aggressive tumor of early childhood. To date, treatment with chemotherapy, surgery, and radiation therapy has resulted in suboptimal outcomes in those with advanced disease. Immune-based treatments hold promise for patients with recurrent or advanced NB. Here, recent preclinical studies and early stage (phase I) clinical trials using cellular therapeutic approaches for NB are reviewed, including studies of natural killer cells, gammadelta T cells, chimeric receptor expressing T cells, dendritic cells, and allogeneic hematopoietic cell transplant.

MeSH Terms
Animals Humans Immunity, Cellular Immunotherapy/methods,trends Neuroblastoma/immunology,therapy
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Verneris Michael R
Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Mayo Mail Code 366, 420 Delaware Street, S.E., Minneapolis, MN 55455, USA. verneris@umn.edu
Wagner John E
References (41)
41 references, click to expand
  1. Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma.
    Cancer Gene Ther. 2005 Aug;12(8):699-707 PMID: 15846368
  2. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
    Cancer Res. 2001 Dec 1;61(23):8513-9 PMID: 11731436
  3. Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines.
    J Neuroimmunol. 2000 Jul 24;107(2):220-5 PMID: 10854660
  4. Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation.
    J Immunother. 2005 Jan-Feb;28(1):73-8 PMID: 15614047
  5. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Cancer Res. 2002 Nov 1;62(21):6178-86 PMID: 12414645
  6. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group.
    J Clin Oncol. 1994 Nov;12(11):2382-9 PMID: 7964954
  7. gammadelta T cells: a new frontier for immunotherapy?
    Biol Blood Marrow Transplant. 2005 Mar;11(3):161-8 PMID: 15744234
  8. Unrelated, HLA-mismatched multiple human umbilical cord blood transfusion in four cases with advanced solid tumors: initial studies.
    Blood Cells. 1994;20(2-3):285-92 PMID: 7749108
  9. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma.
    Blood. 2003 Mar 1;101(5):1718-26 PMID: 12406881
  10. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients.
    Blood. 2002 Oct 1;100(7):2554-61 PMID: 12239169
  11. Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma.
    Br J Cancer. 1998 Aug;78(4):528-33 PMID: 9716039
  12. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
    Clin Cancer Res. 2006 Jul 1;12(13):3993-6 PMID: 16818697
  13. Evidence of graft-versus-tumor effect in refractory metastatic neuroblastoma.
    Transplantation. 2006 Jul 15;82(1):142-4 PMID: 16861958
  14. Neuroblastoma update.
    Curr Opin Oncol. 2005 Jan;17(1):19-23 PMID: 15608507
  15. Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial.
    J Immunother (1991). 1992 May;11(4):274-85 PMID: 1599913
  16. Human gammadelta T lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells.
    J Immunother. 2000 Sep-Oct;23(5):536-48 PMID: 11001547
  17. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor.
    J Pediatr Surg. 2007 Jan;42(1):54-61; discussion 61 PMID: 17208541
  18. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells.
    Clin Cancer Res. 2005 Jun 15;11(12):4561-70 PMID: 15958642
  19. Clinical ineffectiveness of IL-2 and/or IFN alpha administration after autologous PBSC transplantation in pediatric oncological patients.
    Pediatr Hematol Oncol. 2000 Jan-Feb;17(1):31-44 PMID: 10689713
  20. The function of gammadelta T cells in innate immunity.
    Curr Opin Immunol. 2006 Feb;18(1):31-8 PMID: 16337364
  21. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation.
    Bone Marrow Transplant. 1994 Jul;14(1):37-46 PMID: 7951119
  22. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma.
    Blood. 1998 Sep 15;92(6):1941-9 PMID: 9731051
  23. Advances in the diagnosis and treatment of neuroblastoma.
    Oncologist. 2003;8(3):278-92 PMID: 12773750
  24. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction.
    Cancer Res. 2004 Dec 15;64(24):9180-4 PMID: 15604290
  25. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
    Clin Cancer Res. 2005 Dec 1;11(23):8486-91 PMID: 16322312
  26. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.
    Blood. 2004 Apr 15;103(8):3065-72 PMID: 15070686
  27. Immunogenicity of human neuroblastoma.
    Ann N Y Acad Sci. 2004 Dec;1028:69-80 PMID: 15650233
  28. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation.
    Bone Marrow Transplant. 2003 Jul;32(1):103-6 PMID: 12815485
  29. Induction of proliferation and augmented cytotoxicity of gammadelta T lymphocytes by bisphosphonate clodronate.
    Blood. 2001 May 1;97(9):2917-8 PMID: 11345090
  30. Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients.
    Ann Oncol. 2005 Jul;16(7):1199-206 PMID: 15849223
  31. Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy.
    Med Pediatr Oncol. 2000 Dec;35(6):712-5 PMID: 11107153
  32. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma.
    Hum Gene Ther. 1998 Jun 10;9(9):1303-11 PMID: 9650615
  33. Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
    Blood. 2003 Jul 1;102(1):200-6 PMID: 12623838
  34. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
    Mol Ther. 2007 Apr;15(4):825-33 PMID: 17299405
  35. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
    N Engl J Med. 1999 Oct 14;341(16):1165-73 PMID: 10519894
  36. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study.
    Cancer. 1995 Jun 15;75(12):2959-65 PMID: 7773948
  37. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.
    Annu Rev Immunol. 2001;19:197-223 PMID: 11244035
  38. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma.
    Cancer. 2005 Mar 15;103(6):1280-91 PMID: 15693021
  39. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
    J Gene Med. 2004 Jun;6(6):704-11 PMID: 15170741
  40. NK cell receptors.
    Annu Rev Immunol. 1998;16:359-93 PMID: 9597134
  41. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications.
    Neoplasia. 2006 Oct;8(10):833-42 PMID: 17032500
Article Info
Journal
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
Abbr.
J Neuroimmune Pharmacol
ISSN
1557-1904
DOI
10.1007/s11481-007-9065-3
Email
verneris@umn.edu
Published
2007-06-00
Epub
2007-00-02
Pages
134-9
Language
English
Region
United States
NLM ID
101256586
Subset
IM
External Links
PubMed source DOI: 10.1007/s11481-007-9065-3 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2